SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal trades with traction on the BSE

31 Jul 2014 Evaluate

Hikal is currently trading at Rs. 618.00, up by 8.30 points or 1.36% from its previous closing of Rs. 609.70 on the BSE.

The scrip opened at Rs. 614.00 and has touched a high and low of Rs. 625.50 and Rs. 611.00 respectively. So far 438 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 656.00 on 21-Jul-2014 and a 52 week low of Rs. 386.50 on 31-Jul-2013.

Last one week high and low of the scrip stood at Rs. 650.00 and Rs. 605.70 respectively. The current market cap of the company is Rs. 1016.00 crore.

The promoters holding in the company stood at 68.77% while Institutions and Non-Institutions held 13.45% and 17.78% respectively.

Hikal has successfully completed an inspection by European Directorate for the Quality of Medicines (EDQM) at its manufacturing facility at Bangalore. The primary focus of the inspection was the adherence to compliance and implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal products in the European Union.

The inspection concluded that the company operated in accordance with the rules and regulations of the governing authorities based in the European Union and Hikal’s adherence to the highest standards of product quality and global regulatory compliance procedures as part of its fundamental value system. The successful completion of this audit is a positive reflection of company’s people, systems and procedures and commitment to Company's global customer base.

Hikal is a provider of solutions & reliable long-term outsourcing partner to companies in the Pharmaceuticals, Crop Protection, Animal health, and Specialty Chemicals industry. The company has been supplying key active ingredients (AI) and intermediates, manufactured using stringent global quality standards, for its customers in the United States, Europe and Japan.

Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×